$224.00
arrow_drop_down0.65%Is BDX a Buy or Sell based on AI Analysis?
Fundamental Analysis
Becton Dickinson and Co shows strong financial health with a current ratio of 1.08, indicating the company has enough current assets to cover its short-term liabilities. Additionally, the company's debt-to-equity ratio of 0.64 suggests a conservative approach to financing, with lower financial risk. The company's return on equity of 5.13% reflects the company's ability to generate profit from shareholders' equity, although there is room for improvement to maximize returns for investors. Moreover, Becton Dickinson and Co's dividend yield of 1.61% and consistent annual dividends per share of $3.68 demonstrate a commitment to returning value to shareholders over the long term. Furthermore, Becton Dickinson and Co's revenue growth of 2.66% indicates a steady increase in sales, although the average sales growth of -0.36% over three years suggests some fluctuations in the company's performance. The company's gross margin of 42.17% and operating margin of 10.69% reflect the company's efficiency in managing production costs and generating profits. The enterprise value to revenue ratio of 4.25 signifies the company's valuation relative to its revenue, highlighting the company's attractiveness as an investment option. Additionally, the company's solid free cash flow margin of 10.92% indicates the company's ability to generate cash after accounting for operating expenses and capital expenditures, providing flexibility for future investments and growth opportunities.
Positive Development
Becton Dickinson & Co. has been making efforts to improve cervical cancer screening by collaborating with Camtech Health, a digital health company, to provide an option for women to self-collect samples in the privacy of their own homes. The company's Q4 2023 investor letter from Atlantic's Core Equity Composite showed a total return of 12.95% gross of fees, indicating the company's strong performance in the market. The company has been consistently increasing its stock price in recent months, with a significant increase from 240.66 to 241.72 from February 20 to 26.
Negative Development
Despite the positive developments, the company's stock has underperformed in recent weeks, including on Monday and Friday, indicating potential weakness in the company's performance. BDX's stock price has been fluctuating, with a decrease from 241.72 to 235.31 from February 26 to March 1. The company's financial ratios, such as the current ratio and the debt-to-equity ratio, indicate potential financial instability.
Technical Analysis
Becton Dickinson and Co (BDX) currently has a neutral technical rating, with a combination of buy and hold indicators for the month of March. The stock has shown a slight decrease of -4.19% in price over the past seven days, indicating some short-term price weakness. However, the stock has a positive score in multiple market and industry benchmarks, suggesting strong long-term potential. The company's beta of 0.45 indicates that the stock is less volatile than the overall market, which may appeal to conservative investors looking for stability. Additionally, Becton Dickinson and Co's technical analysis shows that the stock has a technical buy indicator count of 3 for the month, with indicators such as ATR, WILLR, and STOCHRSI signaling potential buying opportunities. The stock also has a cumulative multiple of 16.4, indicating that the stock has historically outperformed the market in terms of returns. With a last split ratio of 1025:1000 and a positive outlook for analyst forecasted price changes, BDX may be an attractive option for investors seeking growth potential in the healthcare sector.
Conclusion and recommendation
Based on the data provided, Becton Dickinson and Co (BDX) appears to be a stable and established healthcare company with a strong financial position. The company has a market capitalization of $68.06 billion and a price-to-earnings ratio of 54.15, indicating solid valuation. BDX also offers a dividend yield of 1.61% and has a history of consistent dividend payouts, with an annual dividend per share of $3.68. Furthermore, BDX has a healthy balance sheet, with assets of $52.27 billion and liabilities of $26.94 billion. The company's return on equity of 5.13% and return on assets of 3.12% suggest efficient use of capital and resources. In conclusion, Becton Dickinson and Co presents an attractive investment opportunity for long-term investors looking for stability and dividend income in the healthcare sector. The company's strong financial metrics, including solid revenue growth, healthy margins, and a history of dividend payments, indicate a robust business model. While the stock may not offer high growth potential in the short term, BDX's consistent performance and financial stability make it a reliable choice for investors seeking consistent returns. Overall, Becton Dickinson and Co is a well-established company with a solid track record in the healthcare industry, making it a promising investment option for risk-averse investors.